Literature DB >> 31023194

Use of sliding transphyseal flexible intramedullary nailing in pediatric osteogenesis imperfecta patients.

Dmitry Popkov, Arnold Popkov, Eduard Mingazov.   

Abstract

In our country, the sliding Flexible Intramedullary Nailing is used alone or in combination with Ilizarov frame in children with osteogenesis imperfecta. The study assesses the results of sliding intramedullary nailing in deformity correction in severe types of osteogenesis imperfecta. We retrospectively reviewed 17 consecutive cases (mean age 5.2 y.o.) of types III, IV and VII of osteogenesis imperfecta. In group I (9 patients) the transphyseal FIN was performed using titanium nails. Sliding flexible intramedullary nailing was associated with Ilizarov frame in group II in 8 children. Patients in group I had overall complication rate of 88.9%: proximal nail migration (3), early secondary torsional displacement (4), non-telescoping (12), angular deformity (2), delayed or non-union (2). The reoperation rate was 100%. In group II we observed complications in 6 patients: nail migration (2), bowing of femur (2), non-telescoping (3). The reoperation rate was 87.5%. Flexible intramedullary nailing allows realignment and good functional outcomes. Its major disadvantage is an important complication rate and related reoperation rate. The use of Ilizarov frame provides additional stability and allows early weight-bearing.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31023194

Source DB:  PubMed          Journal:  Acta Orthop Belg        ISSN: 0001-6462            Impact factor:   0.500


  2 in total

1.  Combined technique of titanium telescopic rods and external fixation in osteogenesis imperfecta patients: First 12 consecutive cases.

Authors:  Dmitry Popkov; Tamara Dolganova; Eduard Mingazov; Dmitry Dolganov; Andrey Kobyzev
Journal:  J Orthop       Date:  2020-06-20

Review 2.  Osteogenesis Imperfecta-Who Needs Rodding Surgery?

Authors:  François R Fassier
Journal:  Curr Osteoporos Rep       Date:  2021-03-01       Impact factor: 5.096

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.